Windtree Therapeutics Inc (WINT) - Financial and Strategic SWOT Analysis Review
Windtree Therapeutics Inc (WINT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Windtree Therapeutics Inc (Windtree Therapeutics) is a biopharmaceutical company that focuses on developing its drug product candidates for the treatment of pulmonary and cardiovascular diseases. The company’s lead development programs are istaroxime, for treating acute decompensated heart failure (ADHF) and cardiogenic shock; Aerosurf, a lucinactant for inhalation, and lyophilized KL4 surfactant intratracheal suspension, both for treating respiratory distress syndrome (RDS) in premature infants; KL4 surfactant for the treatment of lung injury effected by sever Covid-19 infection; oral SERCA2a activators for chronic heart failure; Eleison Oncology for ADS; CVI-IST2 for oral heart failure and rostafuroxin for treating genetically associated hypertension. The company benefits from proprietary technology platform Aerosol Delivery System (ADS) with pulmonary surfactants or in combination with other products to treat pediatric and adult respiratory disorders. The company operates in Taiwan, Milan, Taipei, and Italy. Windtree Therapeutics is headquartered in Warrington, Pennsylvania, the US.
Windtree Therapeutics Inc Key Recent Developments
Nov 10,2021: Windtree Therapeutics Reports Third Quarter 2021 Financial Results and Provides Key Business Updates
Aug 02,2021: Windtree Appoints Randall White, Ph.D., as Vice President, Clinical Program Management
Jul 07,2021: Windtree to Present at the Ladenburg Thalmann 2021 Healthcare Conference (Virtual)
Jul 01,2021: Windtree Appoints Diane Carman, Esq. as Senior Vice President and General Counsel
May 13,2021: Windtree Therapeutics Reports First Quarter 2021 Financial Results and Provides Key Business Updates
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Windtree Therapeutics Inc (Windtree Therapeutics) is a biopharmaceutical company that focuses on developing its drug product candidates for the treatment of pulmonary and cardiovascular diseases. The company’s lead development programs are istaroxime, for treating acute decompensated heart failure (ADHF) and cardiogenic shock; Aerosurf, a lucinactant for inhalation, and lyophilized KL4 surfactant intratracheal suspension, both for treating respiratory distress syndrome (RDS) in premature infants; KL4 surfactant for the treatment of lung injury effected by sever Covid-19 infection; oral SERCA2a activators for chronic heart failure; Eleison Oncology for ADS; CVI-IST2 for oral heart failure and rostafuroxin for treating genetically associated hypertension. The company benefits from proprietary technology platform Aerosol Delivery System (ADS) with pulmonary surfactants or in combination with other products to treat pediatric and adult respiratory disorders. The company operates in Taiwan, Milan, Taipei, and Italy. Windtree Therapeutics is headquartered in Warrington, Pennsylvania, the US.
Windtree Therapeutics Inc Key Recent Developments
Nov 10,2021: Windtree Therapeutics Reports Third Quarter 2021 Financial Results and Provides Key Business Updates
Aug 02,2021: Windtree Appoints Randall White, Ph.D., as Vice President, Clinical Program Management
Jul 07,2021: Windtree to Present at the Ladenburg Thalmann 2021 Healthcare Conference (Virtual)
Jul 01,2021: Windtree Appoints Diane Carman, Esq. as Senior Vice President and General Counsel
May 13,2021: Windtree Therapeutics Reports First Quarter 2021 Financial Results and Provides Key Business Updates
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
SECTION 1 - ABOUT THE COMPANY
Windtree Therapeutics Inc - Key Facts
Windtree Therapeutics Inc - Key Employees
Windtree Therapeutics Inc - Key Employee Biographies
Windtree Therapeutics Inc - Major Products and Services
Windtree Therapeutics Inc - History
Windtree Therapeutics Inc - Company Statement
Windtree Therapeutics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
Windtree Therapeutics Inc - Business Description
Product Category: Grant revenue
Performance
Product Category: License Revenue with Affiliate
Performance
R&D Overview
Windtree Therapeutics Inc - Corporate Strategy
Windtree Therapeutics Inc - SWOT Analysis
SWOT Analysis - Overview
Windtree Therapeutics Inc - Strengths
Windtree Therapeutics Inc - Weaknesses
Windtree Therapeutics Inc - Opportunities
Windtree Therapeutics Inc - Threats
Windtree Therapeutics Inc - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Windtree Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Windtree Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Windtree Therapeutics Inc, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Nov 10, 2021: Windtree Therapeutics Reports Third Quarter 2021 Financial Results and Provides Key Business Updates
Aug 02, 2021: Windtree Appoints Randall White, Ph.D., as Vice President, Clinical Program Management
Jul 07, 2021: Windtree to Present at the Ladenburg Thalmann 2021 Healthcare Conference (Virtual)
Jul 01, 2021: Windtree Appoints Diane Carman, Esq. as Senior Vice President and General Counsel
May 13, 2021: Windtree Therapeutics Reports First Quarter 2021 Financial Results and Provides Key Business Updates
Mar 29, 2021: Windtree Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides Key Business Updates
Mar 15, 2021: Windtree to Present at the Oppenheimer 31st Annual Healthcare Conference
Mar 08, 2021: Windtree to Present at the H.C. Wainwright Global Life Sciences Conference
Feb 04, 2021: Windtree strengthens its board by appointing three new directors
Feb 03, 2021: Windtree Therapeutic announces board changes
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
Windtree Therapeutics Inc - Key Facts
Windtree Therapeutics Inc - Key Employees
Windtree Therapeutics Inc - Key Employee Biographies
Windtree Therapeutics Inc - Major Products and Services
Windtree Therapeutics Inc - History
Windtree Therapeutics Inc - Company Statement
Windtree Therapeutics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
Windtree Therapeutics Inc - Business Description
Product Category: Grant revenue
Performance
Product Category: License Revenue with Affiliate
Performance
R&D Overview
Windtree Therapeutics Inc - Corporate Strategy
Windtree Therapeutics Inc - SWOT Analysis
SWOT Analysis - Overview
Windtree Therapeutics Inc - Strengths
Windtree Therapeutics Inc - Weaknesses
Windtree Therapeutics Inc - Opportunities
Windtree Therapeutics Inc - Threats
Windtree Therapeutics Inc - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Windtree Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Windtree Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Windtree Therapeutics Inc, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Nov 10, 2021: Windtree Therapeutics Reports Third Quarter 2021 Financial Results and Provides Key Business Updates
Aug 02, 2021: Windtree Appoints Randall White, Ph.D., as Vice President, Clinical Program Management
Jul 07, 2021: Windtree to Present at the Ladenburg Thalmann 2021 Healthcare Conference (Virtual)
Jul 01, 2021: Windtree Appoints Diane Carman, Esq. as Senior Vice President and General Counsel
May 13, 2021: Windtree Therapeutics Reports First Quarter 2021 Financial Results and Provides Key Business Updates
Mar 29, 2021: Windtree Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides Key Business Updates
Mar 15, 2021: Windtree to Present at the Oppenheimer 31st Annual Healthcare Conference
Mar 08, 2021: Windtree to Present at the H.C. Wainwright Global Life Sciences Conference
Feb 04, 2021: Windtree strengthens its board by appointing three new directors
Feb 03, 2021: Windtree Therapeutic announces board changes
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
LIST OF TABLES
Windtree Therapeutics Inc, Key Facts
Windtree Therapeutics Inc, Key Employees
Windtree Therapeutics Inc, Key Employee Biographies
Windtree Therapeutics Inc, Major Products and Services
Windtree Therapeutics Inc, History
Windtree Therapeutics Inc, Subsidiaries
Windtree Therapeutics Inc, Key Competitors
Windtree Therapeutics Inc, Ratios based on current share price
Windtree Therapeutics Inc, Annual Ratios
Windtree Therapeutics Inc, Annual Ratios (Cont...1)
Windtree Therapeutics Inc, Interim Ratios
Windtree Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Windtree Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Windtree Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
Windtree Therapeutics Inc, Key Facts
Windtree Therapeutics Inc, Key Employees
Windtree Therapeutics Inc, Key Employee Biographies
Windtree Therapeutics Inc, Major Products and Services
Windtree Therapeutics Inc, History
Windtree Therapeutics Inc, Subsidiaries
Windtree Therapeutics Inc, Key Competitors
Windtree Therapeutics Inc, Ratios based on current share price
Windtree Therapeutics Inc, Annual Ratios
Windtree Therapeutics Inc, Annual Ratios (Cont...1)
Windtree Therapeutics Inc, Interim Ratios
Windtree Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Windtree Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Windtree Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
LIST OF FIGURES
Windtree Therapeutics Inc, Performance Chart (2016 - 2020)
Windtree Therapeutics Inc, Ratio Charts
Windtree Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Windtree Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021
Windtree Therapeutics Inc, Performance Chart (2016 - 2020)
Windtree Therapeutics Inc, Ratio Charts
Windtree Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Windtree Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021